"Estrogen" medication from_date:2012

Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment Technology appraisal guidance Published: 5 February 2025 www.nice.org.uk/guidance/ta1036 © NICE 2025. All rights reserved in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should

Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer. As the prognosis for endometrial cancer is excellent, management of the effects of estrogen deprivation has an important influence on quality of life. We examined the trends in the use of estrogen replacement therapy (ERT) and non-hormonal medications among patients with uterine cancer following -and-postoperative changes in ERT and non-hormonal medication use between groups. The trends in postoperative use of ERT were assessed and tested using Cochran-Armitage trend tests. A total of 19,700 patients with uterine cancer and 185,150 controls were identified. Overall, postoperative ERT use decreased for both age groups and for patients with and without uterine cancer. The DID in ERT use between those

Tibolone (Tibella) - for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health * Taxes * More servicesYou are here: 1. HomeSummary Basis of Decision - - Health Canada * Drugs * Natural Health Products * Medical Devices * Review Decisions * Summary Safety Review * Summary Basis of Decision * Regulatory Decision Summary * Submit a report * Report a side effect * Report a serious adverse drug reaction (for hospitals

-dose vaginalestrogen can be used after shared decision mak-ing between the patient, gynecologist, andoncologist.Obstetrician–gynecologists can play an important rolein the shared decision-making process by providing dataon the safety of low-dose vaginal estrogen to patientsand their medical oncologists. Clear communication witha patient’s medical oncologist, if possible, will supportthe Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer CLINICAL CONSENSUSNUMBER 2DECEMBER 2021(REPLACES COMMITTEE OPINION NO. 659, MARCH 2016)Treatment of Urogenital Symptoms in Individuals With aHistory of Estrogen-dependent Breast CancerCommittee on Clinical Consensus–Gynecology. This Committee Opinion was developed by the American College

The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups. The Women's Health Initiative (WHI) randomized trial identified age differences in the benefit-risk profile of estrogen-alone (ET) use. The impact of WHI trial on disease-associated medical expenditures attributable to subsequent decreased ET utilization has , however, not been measured. Therefore, the objective of this analysis was to quantify the age-specific disease-associated medical expenditures attributable to reduced ET utilization after the WHI Hormone Therapy (HT) trials. Population-level disease counts and associated expenditures between 2003 and 2015 were compared between an observed ET-user population versus a hypothetical ET-user population

Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer – Update Estrogen and Progesterone Receptor… | College of American Pathologists GroupCAP_logo_rgb[1]User Skip to Main Content * Access e-LAB Solutions Suite Down Arrow * ELSS Main Page * Organization Profile * Result Form Data Entry * Evaluation Reports * Checklists * Competency Assessment Program * Join the CAP * Shopping Cart Shop * Login CAP Logo * Member Resources Down Arrow * Join / Renew * Residents * Medical Students * New in Practice * House of Delegates * Practice Management * Pathology Careers * Councils and Committees * Advocacy Down Arrow * Payments for Pathology Services * Lobbying and Political Action

SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16?-[18F]Fluoro-17?-Estradiol PET Breast ER PET procedure guidelines – page 1 SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[18F]Fluoro-17β-Estradiol PET David Mankoff1*, Sona Balogova2,3*, Lisa Dunnwald4 , Saint Louis, MO, USA 6University of Groningen, Groningen, Netherlands 7University of Padova, Padova, Italy 8Champalimaud Center for the Unknown, Champalimaud Foundation, Lisbon, Portugal 9Leiden University Medical Center, Leiden, Netherlands 10University of Wisconsin, Madison, WI, USA 11University of Washington, Seattle, WA, USA 12Hoag Family Cancer Institute, Newport Beach, CA, USA *Both

cream use per medication diary). Of 206 postmenopausal patients, 199 were randomized and 186 underwent surgery; 164 (88.2%) provided 36-month data. Mean (SD) age was 65 (6.7) years; characteristics were similar at baseline between groups. Composite surgical failure rates were not significantly different for the estrogen vs. placebo groups through 36 months with model-estimated failure rates of 32.6 Three-Year Outcomes of a Randomized Clinical Trial of Perioperative Vaginal Estrogen as Adjunct to Native Tissue Vaginal Apical Prolapse Repair As the muscular and connective tissue components of the vagina are estrogen-responsive, clinicians may recommend vaginal estrogen to optimize tissues preoperatively and as a possible means to reduce prolapse recurrence, but long-term effects

deviation 5 years). A purposeful sample of 36 women also participated in semistructured qualitative interviews.InterventionsThe ECLIPSE trial randomised participants to either the levonorgestrel-releasing intrauterine system (52 mg) or the usual medical treatment (oral tranexamic acid, mefenamic acid, combined oestrogen–progestogen or progesterone alone, chosen as clinically appropriate by general Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study Text onlyJournals LibraryNHS NIHR - National Institute for Health and Care ResearchSelectEMEGHRHSDRHTAPGfARPHR AdvancedJournalsEfficacy and Mechanism EvaluationGlobal Health ResearchHealth and Social Care Delivery ResearchHealth Technology AssessmentProgramme

pharmacological ESR1 inhibition with fulvestrant reversed hernias and restored normal muscle architecture. Multiomic analyses on in vitro LAM fibroblasts unveiled an estrogen/ESR1-mediated activation of a distinct profibrotic cistrome and gene expression signature, concordant with observations in inguinal hernia tissues in human males. Our findings hold significant promise for prospective medical interventions Estrogen receptor alpha ablation reverses muscle fibrosis and inguinal hernias. Fibrosis of the lower abdominal muscle (LAM) contributes to muscle weakening and inguinal hernia formation, an ailment affecting a noteworthy fifty percent of men by age 75, necessitating surgical correction as the singular therapy. Despite its prevalence, the mechanisms driving LAM fibrosis and hernia development

% reduction of the risk of developing breast cancer in women at high risk. With the advent of newer medications targeting ERα-positive breast cancer, tamoxifen is now mainly used as adjuvant therapy for lower-risk premenopausal breast cancer and cancer prevention. It is widely accepted that tamoxifen as a selective estrogen receptor modulator (SERM) exerts its therapeutic effect by competitively binding Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen? Tamoxifen is one of the most widely used anticancer drugs in the world. It is a safe drug with generally well-tolerated side effects and has been prescribed for the treatment of early-stage and advanced-stage or metastatic estrogen receptor alpha (ERα/ESR1) -positive breast cancer. Tamoxifen therapy also provides 38

, and there is insufficient evidence to routinely recommend methotrexate for medication management of EPL. Letrozole. Letrozole is an aromatase inhibitor that reduces the synthesis of estrogen. A recent RCT from China concluded that pre-treatment with 3 days of letrozole 10 mg daily prior to vaginal misoprostol was noninferior to pretreatment with mifepristone to treat EPL, with efficacy at 42 days of follow-up of 97.8 Society of Family Planning Clinical Recommendation: Medication management for early pregnancy loss Contents lists available at ScienceDirect Contraception journal homepage: www.elsevier.com/locate/contraception Society of Family Planning Clinical Recommendation: Medication management for early pregnancy loss★,☆,☆☆ Jessica L. Tarleton a,b,⁎, Lyndsey S. Benson c, Ghazaleh Moayedi d, Jayme Trevino

May 31, 2023) from 87 health care organizations. The TriNetX database was searched for medical records for female patients with and without exogenous estrogen exposure according to their chronological age. Cohort 1 included 731 366 female patients aged 18 to 45 years old with regular oral contraceptive (OC) intake and cohort 2 included 3 886 568 patients in the same age group who did not use OC Exogenous Estrogen in the Development of Head and Neck Cancer. Sex differences in head and neck cancer (HNC) incidence suggest a potential contribution of sex hormones. To assess the role of exogenous estrogen exposure in the development of HNC in female patients. This large multicenter cohort study using clinical records from the TriNetX real-world database included 20 years of data (through

Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients. Neuroendocrine tumors (NET) are malignant neoplasms that can be associated with specific hormonal syndromes. We describe a novel syndrome of postmenopausal vaginal bleeding and ovarian estradiol overproduction due to ovarian NET localizations. An extensive workup was performed for two index patients with ovarian metastases of small bowel neuroendocrine tumors and symptoms of postmenopausal vaginal bleeding. Clinically significant ovarian estrogen production was demonstrated by a combination of ovarian vein sampling and normalization of circulating estrogen levels after oophorectomy. Immunohistochemical analyses revealed marked aromatase immunoactivity in the ovarian NET cells, while CYP17A1 and SF-1

, testosterone, and estrogen and cognition and symptoms in men with SSD, considering antipsychotic medication. This cross-sectional study included 128 men with SSD and 44 healthy men from two trials. Patients were divided into a prolactin-sparing (n = 53) and prolactin-raising group (n = 75) based on antipsychotic medication. We examined the association between hormones (testosterone, estrogen and prolactin The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen. Certain antipsychotics elevate prolactin levels in patients with schizophrenia spectrum disorders (SSD), potentially affecting cognition, symptoms, and hormone levels. This study examines the association between prolactin

The risks and benefits of high-dose antipsychotic medication COLLEGE REPORT CR190The risks and benefits of high-dose antipsychotic medication(November 2014) Revised January 2023How to cite this publication: Royal College of Psychiatrists (2014; January 2023 revision) Report CR190: The risks and benefits of high-dose antipsychotic medication © 2023 The Royal College of PsychiatristsCollege for efficacy 19Switching medication 20Clinical implications 21Relapse prevention in schizophrenia 22Pharmacological rationale 22Evidence for efficacy 23Clinical implications 24Acute violence and emergency tranquillisation 25Background 25Clinical implications 29Persistent aggression 30Clinical implications

taking medications that interact with anastrozole The details: Adverse Effect Summary Comparison* Potentially serious side effects: Less serious side effects: Drug Blood clots (Thrombosis) Endometrial (uterine) cancer Osteoporosis (thin bones) Hot flushes - sweats Vaginal changes Joint/muscle aches Cataracts Selective Estrogen Receptor Modulators (SERMS) Tamoxifen Rare Rare May help prevent Common Medications to lower the risk of breast cancer Version 7, approved by COSA Council 22 March 2024 Page 1 of 10 Medications to lower the risk of breast cancer CLINICIAN GUIDE Introduction Risk reducing medication is an efficacious breast cancer prevention option. It is an option for high- risk women who do not wish to undergo (or who wish to postpone) risk-reducing mastectomy. It is also an option

Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) ACMG PRACTICE RESOURCEManagement of individuals with heterozygousgermline pathogenic variants inATM: A clinicalpractice resource of the American College of MedicalGenetics and Genomics (ACMG)Tuya Pal1, Katherine R. Schon2 for medical geneticists and other clinicians to help them provide quality medicalservices. Adherence to this practice resource is completely voluntary and does not necessarily assure a successful medical outcome. This practice resourceshould not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining thesame results

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomar Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive resources Clinical Trial Lancet Oncol Actions * Search in PubMed * Search in NLM Catalog * Add to Search . 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression

rectus muscles. We report a 30-year-old transgender female on long-term estrogen therapy who underwent strabismus surgery involving recessions of both lateral rectus muscles, the right inferior rectus muscle, and the left superior rectus muscle. The left eye developed severe ASI with hypotony maculopathy that was resistant to topical medications, oral steroids, anterior chamber reformation Anterior segment ischemia following strabismus surgery in a young adult using gender-affirming estrogen hormone therapy. Well-known risk factors for anterior segment ischemia (ASI) following strabismus surgery include ipsilateral surgery on three or more rectus muscles, older age, and vasculopathy. ASI is rarely reported in young patients following uneventful strabismus surgery on two ipsilateral